Sahara Growth Fund (G) Outperforms The Sensex Over All Time Periods

Background: Sahara Asset Management Company Private Ltd. is a wholly owned by subsidiary of Sahara India Financial Corporation Limited, (SIFCL) is the flagship company of Sahara India Group. Incorporated in 1987, SIFCL is the First Residuary Non-Banking Company (RNBC) in India that has been granted certificate of registration by RBI and is considered to be a leading public deposit mobilization company in the Private sector. The Sahara India Group has over the years emerged as a multi-service and multi-product business conglomerate with diverse interests in fields such as Aviation, Life Insurance, Para banking, Housing, Infrastructure & Tourism, Consumer Products, and Media & Entertainment. The fund house manages assets worth Rs.197.51 crore at the end of September 2007.

Sahara Growth Fund (G) an open-ended equity-diversified scheme launched in July 2002.The objective of the scheme is to achieve long-term capital appreciation by investing 80-100% in equities and balance in money market instruments. The minimum investment amount is Rs.3000 and in multiples of Rs.1000 thereafter. The unit NAV of the scheme was Rs.73.80 as on 1 November 2007.

Portfolio: The total net assets of the scheme increased by 1.07 crore to Rs.4.73 crore in September 2007.

Sahara Growth Fund (G) took fresh exposure to eleven stocks in September 2007. The scheme has purchased 11,031 units (4.51%) of NTPC, 6,008 units (2.63%) of Steel Authority of India 1,001 units (2.53%) of ACC, 6,011 units (2.30%) of Cairn India and 6,007 units (2.21%) of GMR Infrastructure among others in September 2007.

The scheme completely exited from Wipro by selling 2,502 units (3.30%), Glaxosmithkline Pharma by selling 997 units (3.19%), HCL Technologies by selling 2,013 units (1.67%) and Tata Steel by selling 800 units (1.51%) among others in September 2007.

Sector-wise, the scheme took fresh exposure to Steel- Sponge Iron at 2.19% in September 2007.

Sector-wise the scheme completely exited from Pharmaceutical- Multinational at 3.19% in September 2007.

The scheme had highest exposure to ITC with 9,499 units (3.81% of portfolio) followed by Crompton Greaves with 5,034units (3.54%), Larsen & Toubro with 548 units (3.26%) and Punjab National Bank with 2,598 units (2.98%) among others in September 2007.

It reduced its exposure to Ranbaxy Laboratories by selling 1,748 units to 1,001 units (by 2.02%), Reliance Petroleum by selling 4,509 units to 4,501 units (1.39%) and Reliance Industries by selling 200 units to 550 units (1.35%) among others in September 2007.

Sector-wise, the scheme had highest exposure to Electric Equipment at 10.28% (9.07% in August 2007), followed by Banks - Public Sector at 9.34% (6.50%), Banks - Private Sector at 8.44% (5.64%) and Power Generation And Supply at 8.10% (2.13%) among others in September 2007.

Sector-wise the scheme had reduced exposure Computers - Software – Large to 1.79% (by 5.35%), Refineries to 5.87% (by 2.79%), Pharmaceuticals - Indian - Bulk Drugs & Formulation to 0.92% (by 2.02%) and Telecommunications - Service Provider to 5.36% (by 1.30%) among others in September 2007.

Performance: The scheme out performed the category average over all time periods.

It has outperformed the Sensex over all time periods.

Over three-month period ended as on 1 November 2007, the scheme posted 30.66% returns outperforming the category average of 22.79%. It outperformed the Sensex that posted 27.57% return during the same period.

Since inception, the scheme posted 665.07% returns outperforming the category average of 312.47%.